10-Q: Sharps Tech Pivots to Solana, Raises $411M, Reports Q3 Loss

Sentiment:

Quarterly Report 14 November 2025 3:57 PM

Sharps Technology, Inc. announced a major strategic shift to a digital asset treasury focused on Solana, raising $411 million, while reporting a significant net loss for Q3 2025 and spinning off its medical device manufacturing.

Capital raiseOn August 25, 2025, the company entered into Cash Securities Purchase Agreements and Cryptocurrency Securities Purchase Agreements, raising aggregate gross proceeds of $411 million. This included $181 million in cash, $137 million in locked SOL, $7 million in unlocked SOL, and $86 million in stablecoin (USDC/USDT).Between September 2, 2025, and September 30, 2025, the company issued 1.5 million shares of common stock under a Controlled Equity Offering (ATM Offering), receiving net proceeds of $14.7 million.On January 29, 2025, the company closed an offering (the 2025 Offering) for approximately $20.0 million in gross proceeds, with net proceeds of $18.2 million.

Worse than expectedThe net loss for the three months ended September 30, 2025, was $(105,333,293), significantly worse than the $(1,685,060) loss in the same period last year.The net loss for the nine months ended September 30, 2025, was $(99,845,153), substantially worse than the $(4,769,774) loss in the prior year.Selling, General and Administrative expenses increased by over 2,000% for the nine-month period, primarily due to a $101.3 million stock-based compensation charge, indicating a significant increase in operational costs.An impairment charge of $7.5 million on fixed assets reflects a write-down of previous investments in the medical device manufacturing segment, indicating underperformance or strategic failure in that area.

Summary

Sharps Technology, Inc. (STSS) has undergone a significant strategic pivot, shifting its primary focus from medical device manufacturing to a digital asset treasury strategy centered on accumulating Solana (SOL).
The company reported a net loss of $105.3 million for the three months ended September 30, 2025, and $99.8 million for the nine months ended September 30, 2025, a substantial increase from the prior year's losses.
Total assets surged to $443.96 million as of September 30, 2025, from $7.31 million at December 31, 2024, primarily due to the acquisition of $404.2 million in digital assets (SOL and USDC).
The company successfully raised $411 million in gross proceeds through August 2025 securities purchase agreements, paid in a combination of cash, locked SOL, unlocked SOL, and stablecoin, with net proceeds of $403 million.
An additional $14.7 million in net proceeds was raised through a Controlled Equity Offering (ATM Offering) between September 2 and September 30, 2025.
The medical device manufacturing operations are being terminated, with a shift to a sales and distribution model, and the Hungarian subsidiary (Safegard Medical Kft) was spun off on October 6, 2025, settling outstanding litigations.
Selling, General and Administrative expenses dramatically increased to $114.57 million for the nine months ended September 30, 2025, largely driven by $101.3 million in stock-based compensation related to warrants issued to a strategic advisor.
The company recognized $15.5 million in realized and unrealized gains on digital assets for the nine months ended September 30, 2025.
An impairment charge of $7.5 million was recorded on long-lived fixed assets due to the pending sale of the Safegard subsidiary.
A share repurchase program of up to $100 million was approved on October 2, 2025, signaling confidence in the company's valuation.

Sentiment

Score: 4

Explanation: The company executed a massive capital raise and strategic pivot into digital assets, which could offer significant upside. However, the substantial net losses, high stock-based compensation, and impairment charges reflect significant operational challenges and a costly transition. The shift to a highly volatile asset class like Solana introduces considerable risk, despite the stated liquidity improvement. The share repurchase program is a positive, but the overall financial performance for the period is poor, and the future is highly speculative.

Positives

Total assets increased dramatically to $443.96 million as of September 30, 2025, from $7.31 million at December 31, 2024, primarily driven by digital asset acquisitions.
Successfully raised $411 million in gross proceeds from August 2025 offerings, significantly bolstering the company's capital base.
The company's new digital asset treasury strategy has resulted in $404.2 million in digital asset holdings (SOL and USDC) and generated $2.21 million in staking revenue for the nine months ended September 30, 2025.
Current liquidity, including $10.5 million cash and $14.7 million USDC, is deemed sufficient to fund planned operations for the next twelve months, alleviating prior going concern doubts.
Approval of a $100 million share repurchase program on October 2, 2025, indicates management's confidence and commitment to shareholder value.
Settlement of all outstanding litigations with Barry Berler and Plastomold Industries Ltd, removing legal uncertainties and associated costs.

Negatives

Reported a substantial net loss of $105.3 million for the three months ended September 30, 2025, and $99.8 million for the nine months ended September 30, 2025, significantly higher than previous periods.
Selling, General and Administrative expenses surged to $114.57 million for the nine months ended September 30, 2025, primarily due to a $101.3 million stock-based compensation charge for warrants issued to a strategic advisor.
Incurred a $7.5 million impairment charge on long-lived fixed assets due to the termination of medical device manufacturing and the spinoff of the Hungarian subsidiary.
The medical device packaging segment recorded a gross margin loss of $2.20 million for the nine months ended September 30, 2025, largely due to inventory reserves and excess manufacturing costs.
Cash used in operating activities increased to $11.74 million for the nine months ended September 30, 2025, from $5.17 million in the prior year.
The company's shift away from medical device manufacturing and R&D activities for its syringe products indicates a failure or significant challenge in its original core business.

Risks

The price of SOL has historically been subject to dramatic fluctuations and is highly volatile, posing significant market risk to digital asset holdings.
Regulatory and accounting treatments for digital assets are uncertain, and new regulations could adversely affect the liquidity or value of SOL.
A decline in the fair value of SOL holdings below carrying value could require recognition of material unrealized losses, causing significant volatility in reported earnings and potentially impacting common stock price.
The treasury policy is highly concentrated in a single digital asset (SOL), making the company disproportionately vulnerable to adverse developments specific to the Solana protocol, validator network, ecosystem, or regulatory environment.
Liquidity risk exists as the company may not be able to liquidate SOL holdings at favorable prices or use them to raise capital during market instability, or due to staking cool-down periods (approximately 48 hours for unstaking liquid SOL).
Operational risks include custody failures, cyber-security risks, and protocol or network disruptions, as digital assets held through custodians lack FDIC/SIPC protections.
Related party transactions with Sol Edge Limited (Consultant) and Sol Markets (Strategic Advisor), both controlled by the brother of the Chief Investment Officer, may not be at arm's length and could create conflicts of interest.
The equity interest granted to the Strategic Advisor (warrants to purchase 6,321,367 shares) could influence decisions, potentially not solely in the best interest of the company or stockholders.

Future Outlook

The company intends to explore strategic acquisitions and investments globally, potentially using proceeds from the sale of SOL to fund these expansion plans. It has hired a Head of Innovation and engineering team members to analyze opportunities and develop its own digital products. The company will no longer engage in research and development activities for medical devices, focusing instead on sales and distribution.

Management Comments

"The Companys addition of the business strategy with digital assets resulting in current investment in Digital Assets of $404.2M primarily from August 2025 and current cash of $10.5M and USDC of $14.7M the Company determined it had sufficient liquidity to fund the Companys planned operations for the next twelve months. The current liquidity no longer raises substantial doubt regarding the Companys ability to continue as a going concern."
"We continue to be in discussions with healthcare companies and distributors for sales of our existing inventory of disposable syringe and prefillable syringe products."
"The Company has been and will continue to prioritize long term growth with regards to its treasury management strategy, potentially using proceeds from the sale of SOL to fund its expansion plans described above."
"The Company intends to explore plans to expand its distribution platform by representing established third-party manufacturers of complementary and synergistic medical products serving a common customer base."
"Sharps Technology is committed to maintaining compliance with all applicable regulatory and quality standards governing the marketing and distribution of medical devices."

Industry Context

Sharps Technology's pivot from medical device manufacturing to a digital asset treasury strategy, particularly focusing on Solana, represents a significant departure from its traditional industry. This move aligns with a broader trend of companies exploring alternative treasury management strategies and exposure to the cryptocurrency market, seeking potential high growth and diversification. However, it also places the company in a highly volatile and rapidly evolving sector with significant regulatory and market risks, contrasting sharply with the more stable, regulated medical device industry. The shift to a distribution-only model for medical devices suggests a strategic retreat from capital-intensive manufacturing, potentially to free up resources for the new digital asset focus.

Comparison to Industry Standards

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer and Board Member	Robert Hayes	Paul K. Danner (as Principal Executive Officer)	2025-08-23	Resignation, mutual agreement (Separation Agreement) with severance and stock options.
Chief Investment Officer and Director	NA	Yuwen (Alice) Zhang	2025-08-25	Appointment as part of strategic pivot to digital assets.
Principal Executive Officer	NA	Paul K. Danner	2025-08-24	Appointment following Robert Hayes' resignation; Mr. Danner was already Executive Chairman.
Chief Financial Officer	Andrew R. Crescenzo	To be determined	2025-12-31	Intent to retire.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Authorized Shares Increase	Shareholders approved an increase in authorized common stock from 1,666,667 shares to 500,000,000 shares.	2025-08-22	Facilitates future equity offerings and capital raises, potentially leading to dilution but also providing flexibility for growth initiatives.
Equity Incentive Plan Adoption	Shareholders approved the Sharps Technology, Inc. 2025 Equity Incentive Plan, providing for the issuance of up to 2,000,000 options and/or restricted stock.	2025-08-22	Allows for compensation and retention of officers, directors, employees, and consultants, aligning incentives with company performance.
Authorized Shares Reduction and Reverse Stock Split	Board approved an amendment to reduce authorized shares from 500,000,000 to 1,666,667 and effect a 1-for-300 reverse stock split.	2025-04-27	Aimed at increasing per-share price, potentially to maintain Nasdaq listing compliance, but also reduces the number of outstanding shares.

Legal Proceedings

On October 6, 2025, the company entered into a confidential settlement agreement and release with Barry Berler, Plastomold Industries Ltd, Plasto Design Solutions, Plasto Design Ltd, and Plasto Technology Group LLC. This agreement resolved all outstanding claims alleged in the litigations, with both parties releasing each other from liability.
As part of the settlement, the company transferred certain assets, including its Hungarian subsidiary Safegard Medical Kft, patents, and registered trademarks, to Plasto Technology.

Related Party Transactions

Consulting services provided by Sol Edge Limited, wholly-owned and controlled by James Zhang (brother of CIO Alice Zhang), amounted to $892,000 for the three months ended September 30, 2025. A prepaid expense of $9.8 million was recorded for the initial annual payment.
Warrants to purchase 6,321,367 shares of common stock, with a fair market value of $101,331,513, were issued to Sol Markets (a strategic advisor wholly-owned and controlled by James Zhang) on August 28, 2025, as part of a strategic advisory consulting agreement.
Accounts payable and accrued liabilities include $106,798 payable to officers and directors as of September 30, 2025.

Stakeholder Impact

**Shareholders:** Significant dilution from recent capital raises (August 2025 offerings, ATM offering) but also potential for value creation from the new digital asset strategy and the $100 million share repurchase program. The substantial net losses and high stock-based compensation could be a concern.
**Employees:** Changes in management roles (CEO resignation, new CIO and PEO appointments, CFO retirement) indicate a restructuring. The shift away from medical device manufacturing may impact employees in that segment, while new hires for the digital asset treasury suggest new opportunities.
**Customers (Medical Device):** The company is shifting to a sales and distribution model for medical devices, no longer manufacturing. This could impact product availability or service, though existing inventory is being marketed.
**Creditors:** The substantial capital raise significantly improved liquidity and reduced going concern doubts, which is positive for creditors. The repayment of $4.2 million in outstanding notes also strengthens the balance sheet.
**Suppliers (Medical Device Manufacturing):** Termination of manufacturing operations will likely lead to cessation of relationships with manufacturing-related suppliers.

Next Steps

Explore strategic acquisitions and investments globally, particularly in the crypto technology sector.
Develop own digital products, supported by a newly hired Head of Innovation and engineering team.
Potentially use proceeds from SOL sales to fund expansion plans.
Continue marketing and distributing existing inventory of disposable and prefillable syringe products.
Identify and appoint a successor Chief Financial Officer following Andrew R. Crescenzo's retirement on December 31, 2025.
Execute the approved $100 million share repurchase program in the open market and negotiated transactions.

Key Dates

Date	Description
2017-07-01	Royalty agreement with Barry Berler for intellectual property purchase.
2017-12-11	Company incorporated in Wyoming.
2018-02-01	Series A Preferred Stock issued to Alan Blackman.
2018-09-01	Royalty Agreement with Barry Berler amended to reduce royalty to 2% and provide for a single $500,000 payment for cancellation of further obligations.
2019-04-18	Authorized common stock increased to 50,000,000 shares.
2019-05-01	Royalty Agreement with Barry Berler further amended to change payment date to on or before May 31, 2021.
2022-03-22	Company completed merger with Sharps Nevada, increasing authorized common stock to 100,000,000 and preferred stock to 1,000,000 shares.
2022-04-13	Company's Initial Public Offering (IPO) declared effective by the SEC.
2022-04-14	Trading of common stock and warrants commenced on Nasdaq Capital Market.
2022-04-19	Company received net proceeds of $14.2 million from IPO; underwriter partially exercised over-allotment option for 170 warrants.
2022-09-30	Formal employment agreement entered with Andrew R. Crescenzo as Chief Financial Officer.
2023-01-24	Board of Directors adopted the 2023 Equity Incentive Plan.
2023-02-03	Company completed a securities purchase agreement (Offering) with institutional investors, receiving net proceeds of approximately $3.2 million.
2023-06-01	Robert Hayes' annual compensation increased to $600,000 retroactive to this date.
2023-09-29	Company completed two simultaneous offerings (Shelf Offering and Private Placement), receiving aggregate gross proceeds of approximately $5.6 million.
2024-04-03	Plastomold Industries Ltd commenced a lawsuit against the Company.
2024-05-20	Company entered into an Amendment to the Asset Purchase Agreement with Nephron and InjectEZ, LLC.
2024-05-30	Company offered warrant inducements to certain warrant holders.
2024-05-31	Company entered into subscription agreements with institutional investors, issuing 636 shares for gross proceeds of $1.6 million.
2024-06-13	Company entered into additional subscription agreements with institutional investors.
2024-06-17	Barry Berler filed a demand for arbitration against the Company.
2024-07-10	Barry Berler commenced a lawsuit against the Company and Alan Blackman.
2024-07-19	$1 million escrow deposit released to Seller (Nephron) as a forfeited agreement cost.
2024-07-24	Company entered into a Supply Agreement with Stericare Solutions, LLC for 520 million units of syringes.
2024-07-30	Shareholders approved the increase of authorized common stock from 100,000,000 to 500,000,000.
2024-08-25	Company entered into an amendment (Series A Amendment) with certain warrant holders to reduce exercise price of Series A Warrants.
2024-09-20	Company entered into a securities purchase agreement and Senior Secured Note for $4,375,000 aggregate principal amount.
2024-10-07	Shareholders approved a proposal to authorize a reverse stock split (not to exceed 1-for-22).
2024-10-15	A 1-for-22 reverse stock split was effective.
2024-12-05	Company entered into subscription agreements with institutional investors, issuing 828 shares for gross proceeds of $484,438.
2024-12-19	Shareholders approved and Board adopted the 2024 Equity Incentive Plan.
2025-01-29	Company closed on the 2025 Offering, receiving gross proceeds of approximately $20.0 million.
2025-02-27	Advisory agreement entered into, with 72,094 warrants to be issued May 5, 2025.
2025-03-28	Stockholders approved a reset of the exercise price for 2025 Warrants to $87.60.
2025-04-23	Board approved an Amendment to the Certificate of Incorporation to reduce authorized shares and effect a 1-for-300 reverse stock split.
2025-04-27	Reduction in authorized shares and 1-for-300 reverse stock split became effective.
2025-04-30	Company received initial purchase order for $400,000 under the Stericare Supply Agreement.
2025-07-15	Company executed a Subscription and Investment Agreement with Paul Danner for 5 shares of Series B Preferred Stock; Board approved 2025 Equity Incentive Plan.
2025-07-17	Sale of Series B Preferred Stock to Paul Danner closed.
2025-08-08	Company assigned the Stericare Supply Agreement to Safegard Medical.
2025-08-21	Company entered into a settlement term sheet with Barry Berler and Plastomold Industries Ltd.
2025-08-22	Shareholders approved the 2025 Equity Incentive Plan and an increase in authorized common stock from 1,666,667 to 500,000,000 shares.
2025-08-23	Robert Hayes resigned from the Board and as CEO; Board approved new Treasury Policy.
2025-08-24	Company adopted a digital asset treasury strategy focused on accumulating Solana (SOL); Paul K. Danner's term as Principal Executive Officer began.
2025-08-25	Company entered into Cash Securities Purchase Agreements and Cryptocurrency Securities Purchase Agreements for private placement offerings; formal employment agreements entered with Yuwen (Alice) Zhang (CIO) and Paul K. Danner (Executive Chairman & PEO).
2025-08-28	Company acquired SOL Equity Limited; entered into a strategic advisory consulting agreement with Sol Markets, issuing warrants.
2025-09-02	Company entered into a Controlled Equity Offering Sales Agreement (ATM Offering) with Cantor Fitzgerald & Co. and Aegis Capital Corp.
2025-09-26	Company entered into Waiver and Consent with certain security holders, extending the resale registration statement filing deadline.
2025-09-30	End of the reporting period for this 10-Q filing.
2025-10-02	Board approved a share repurchase program of up to $100,000,000.
2025-10-06	Company entered into a confidential settlement agreement and release with Barry Berler, Plastomold Industries Ltd, and related entities; entered into an Open Market Share Repurchase Agreement with Cantor Fitzgerald & Co.
2025-10-14	Settlement Agreement and other definitive agreements for the spinoff of the Hungarian subsidiary closed; Stockholder Approval for exercise of Cryptocurrency Pre-Funded Warrants and Stapled Warrants was obtained.
2025-10-23	Initial resale registration statement filed.
2025-10-31	Company holds over 2.0M SOL.
2025-11-14	Filing date of this Quarterly Report on Form 10-Q; 28,226,153 shares of common stock issued and outstanding.
2025-12-31	Andrew R. Crescenzo (CFO) intends to retire from his positions.

Recommendation

hold

Sharps Technology is undergoing a radical transformation, pivoting from a struggling medical device manufacturer to a digital asset treasury company focused on Solana. While the massive capital raise of over $400 million and the subsequent $100 million share repurchase program are strong signals of financial backing and management's confidence, the company reported significant net losses driven by substantial stock-based compensation and asset impairment charges related to the medical device segment's wind-down. The new strategy introduces extreme volatility and regulatory uncertainty inherent in the cryptocurrency market. This is a high-risk, high-reward play. For a seasoned investor, the current situation warrants a 'hold' as the company navigates this complex transition. The potential upside from successful digital asset management and strategic acquisitions is considerable, but the execution risk, market volatility, and the magnitude of recent losses and related party transactions demand careful monitoring before a more definitive stance can be taken. The stock is highly speculative at this juncture.

Keywords

Solana, SOL, Digital Assets, Cryptocurrency, Treasury Strategy, Medical Device Packaging, SEC Filing, 10-Q, Financial Results, Capital Raise, Share Repurchase, Corporate Pivot, Warrants, Stock Compensation, Impairment, Liquidity, Risk Factors

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.